---
schema_version: "secwatch.filing_event.v1"
accession: "0000711404-22-000010"
form_type: "8-K"
ticker: "COO"
cik: "0000711404"
company_name: "COOPER COMPANIES, INC."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:11:00.958125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CooperCompanies Q1 revenue up 16% to $787M; non-GAAP EPS $3.24

## Summary
- Revenue $787.2M (+16% YoY); CooperVision +11% to $561.5M, CooperSurgical +30% to $225.7M.
- GAAP diluted EPS $1.91 (vs $42.31 prior year due to deferred tax benefit); non-GAAP diluted EPS $3.24 (+2%).
- Net debt $2,981.5M after Generate Life Sciences acquisition; adjusted leverage 2.71x.
- FY2022 guidance: revenue $3,261-$3,329M; non-GAAP EPS $13.70-$14.20.

## SEC filing metadata
- accession: 0000711404-22-000010
- form_type: 8-K
- ticker: COO
- cik: 0000711404
- company_name: COOPER COMPANIES, INC.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/0000711404-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/711404/000071140422000010/coo-20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000711404-22-000010
- JSON: https://secwatch.observer/filing/0000711404-22-000010.json
- Plain text: https://secwatch.observer/filing/0000711404-22-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.